--16.   (twice amended) A polypeptide according to claim 13 capable of essentially specific binding to a negatively charged heparan sulphate or heparan sulphate-like molecule.--

--17. (twice amended) A polypeptide according to claim 13 having a weight of about 100-300 kDa.--

Cancel claims 1-12, 18-20, 22, 23, 25-27, and 28-32 without prejudice.

Add the following new claims:

--33.   A medicament made from a polypeptide having a malaria erythrocyte membrane protein comprising an amino-terminal part of the sequence according to SEQ ID NO:1.

--34. A medicament according to claim 22 with a treatment or prevention of malaria, or vaccination against malaria.--

--35.   An isolated polypeptide originating from a malaria erythrocyte membrane protein comprising an amino-terminal part of the sequence according to SEQ ID NO:1 wherein the polypeptides bind to malaria-infected erythrocytes membrane

protein and the polypeptide does not bind to complement receptor 1 or intercellular adhesion molecule 1.

--36.   A polypeptide according to claim 13 comprising domain DBL-1 having 423 amino acids of the sequence according to SEQ ID NO:1 or an analog thereof.--

--37.   A polypeptide according to claim 13 having a weight of 280 kDa.--

--38.   A pharmaceutical composition comprising a polypeptide according to claim 13 in a vaccine.--

R E M A R K S

The application has been amended so as to place it in condition for allowance at the time of the next Official Action.

Claims 13-17, 24, and 33-38 are pending, with claims 13, 14, and 35 being independent.

Claims 1-12, 18-20, 25, 26, 28-31 and 32 are cancelled, without prejudice. These claims are being cancelled because of a restriction requirement. Furthermore, claims 22, 23, and 27 are cancelled without prejudice.

The Official Action rejected former claims 22-23, now claims 33 and 34, under §101 as being directed to non-statutory subject matter. Claims 22 and 23, by amendment, are directed to a composition of the polypeptide as a medicament in claims 33 and

3